We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
5.00 | 0.29% | 1,733.50 | 1,732.50 | 1,733.00 | 1,739.50 | 1,724.50 | 1,733.00 | 4,237,056 | 16:35:18 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 14.48 | 71.35B |
Date | Subject | Author | Discuss |
---|---|---|---|
18/3/2015 13:36 | Don't forget the 1800p + ..... ;0) | tradermichael | |
18/3/2015 12:08 | A 'whoosh' phil :) | scottishfield | |
18/3/2015 12:06 | 1600p + :-) | philanderer | |
17/3/2015 14:30 | Thank you anhar . | redips2 | |
17/3/2015 13:28 | I contacted ADVFN about this and they have confirmed that this is a temporary fault on the portfolio pages which they are working on. | anhar | |
17/3/2015 11:18 | Anhar...Ditto. My monitor shows the news, my portfolio does not . | redips2 | |
17/3/2015 09:58 | Mine has the news indicator and its working fine. News at AV today for example (nothing exciting though) | dr biotech | |
17/3/2015 08:31 | Not related directly to GSK but does anyone know why ADVFN has stopped showing the news indicator against each share in a portfolio? This was a very useful feature where one could see at a glance whether a share had reported any news, regulated or non-regulated, and then click through to it. The RN and NRN columns are still there on the portfolios, it's just that there are no entries in them any longer. | anhar | |
17/3/2015 08:13 | Yes we've mashed that potato supermarky. | madengland | |
16/3/2015 23:36 | The chart indicates lots of resistance north of here. Who knows. Gsk is quite a safe ship to be in. Promising it's north of 1570 and closed. Need to check recent intra day highs. | supermarky | |
16/3/2015 23:26 | That would be perfect TM | gucci | |
16/3/2015 23:26 | That would be perfect TM | gucci | |
16/3/2015 19:17 | WELL, CHART INDICATES MORE LIKE 1800 .... LOL ..... ;0) | tradermichael | |
16/3/2015 15:31 | You reckon? | supermarky | |
16/3/2015 15:02 | heading for straight 1700 | gucci | |
16/3/2015 14:59 | Over the magic potato number 1570 guys woooppppee. | supermarky | |
16/3/2015 09:31 | update from 'the lads' ;-) 16th march Credit Suisse underperform tp 1440p up from 1330p 16th march Barclays overweight tp 1690p | philanderer | |
13/3/2015 18:21 | Seems so TM :-) Good bounce today. | philanderer | |
13/3/2015 12:26 | All publicity is good publicity | tradermichael | |
13/3/2015 10:49 | Very touchy those American companies. | 2hoggy | |
12/3/2015 20:48 | more or less the same in the Telegraph... "n the FTSE 100, which enjoyed a second day of gains after adding 0.59pc to 6761.07, topping the leaderboard was drug group Astrazeneca. Hopes of positive news about its Brilinta heart drug when the results of clinical trials are posted at the weekend lifted the shares 4.1pc to £44.79. "Peers Shire and Glaxosmithkline were also big risers, putting on 2.7pc to £54.55 and 1.9pc to £15.48½ respectively. Glaxo was boosted by news it will sell half its stake in South Africa’s Aspen Pharmacare, which is expected to raise about $890m." | philanderer | |
12/3/2015 18:46 | Sorry...got that earlier post on potential value of Aspen share sale totally wrong..... T/O is a little under £1 billion for the South African entity. Good news on AZN and hope there is more to come with GSK..Sorry again. | cyberian | |
12/3/2015 18:13 | Might see a bid premium on GSK soon at this rate of future growth focus. | gwatson56 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions